PCAC (Pharmacy Compounding Advisory Committee)

The PCAC is the FDA's advisory committee that reviews whether bulk active pharmaceutical ingredients can be used in 503A compounding pharmacies. When a bulk substance is under PCAC review, it means the FDA is evaluating the safety and effectiveness data for that compound in the compounding context. The committee makes recommendations — approve, reject, or request more data — but the FDA makes the final decision. The July 23–24 2026 PCAC meeting is the regulatory event most relevant to the peptide compounding market. BPC-157, TB-500, MOTS-c, DSIP, KPV, Semax, and Epithalon are all on that docket. The outcome will determine whether these compounds can be legally prescribed and compounded through US 503A pharmacies. For the peptide audience, a PCAC review is not a guarantee of approval. The committee has rejected bulk substances before, and some peptides have been through multiple review cycles. The July 2026 meeting is a significant checkpoint, not a foregone conclusion.